Taper Henryk S
Unité de Pharmacocinétique, Métabolisme, Nutrition et Toxicologie Université Catholique de Louvain, Bruxelles, Belgium.
Anticancer Res. 2008 Sep-Oct;28(5A):2727-32.
The alterations of deoxyribonuclease DNase activity in cancer cells were the basis of the utilization of mixed vitamins C and K3 in a nontoxic, adjuvant cancer therapy. In order to localize exactly the altered activities of DNase in cancer cells, histochemical methods were utilized. The deficiency of alkaline and acid DNase activity appeared to be characteristic for non-necrotic cells of malignant human and animal tumors. This enzymatic deficiency appeared in experimental carcinogenesis before the phenotypic signs of malignancy. Tumor promoters directly reduced the activity of both DNases. The incidence of spontaneous malignant human and animal tumors appeared to be inversely proportional to the intensity of the activity of both DNases in normal cells and tissues from which these tumors were derived. The fact that alkaline and acid DNase activity was reactivated during the spontaneous and therapeutically induced necrosis of cancer cells suggests that this enzymatic deficiency of DNase activity in cancer cells was due to the action of specific inhibitors of DNases. Characteristic variations of serum alkaline DNase activity in positive responders to therapy, examined in more than 800 cancer-bearing patients, may be the basis for the development of a useful test for therapeutic prognosis and for monitoring of cancer bearing patients. Acid DNase was selectively reactivated in malignant tumor cells by vitamin C (sodium ascorbate), whereas alkaline DNase was reactivated by vitamin K3. Joint vitamin C and K3 administration produced in vitro and in vivo tumor growth inhibition, potentiation and sensitization of chemo- and/or radiotherapy and a decrease in the number of metastases in animals with experimental tumors. Joint vitamin C and K3 administration may be considered as a possible new, non-toxic, adjuvant cancer therapy, which can be easily introduced into the classic protocols of clinical cancer therapy without any supplementary risk for patients.
癌细胞中脱氧核糖核酸酶（DNase）活性的改变是在无毒辅助癌症治疗中使用混合维生素C和K3的基础。为了精确确定癌细胞中DNase活性的改变，采用了组织化学方法。碱性和酸性DNase活性的缺乏似乎是人类和动物恶性肿瘤非坏死细胞的特征。这种酶活性缺乏在实验性致癌过程中早于恶性肿瘤的表型特征出现。肿瘤启动子直接降低了两种DNase的活性。人类和动物自发性恶性肿瘤的发生率似乎与这些肿瘤所源自的正常细胞和组织中两种DNase活性的强度成反比。癌细胞在自发和治疗诱导的坏死过程中碱性和酸性DNase活性被重新激活，这一事实表明癌细胞中DNase活性的这种酶缺乏是由于DNase特异性抑制剂的作用。在800多名癌症患者中检测到的治疗阳性反应者血清碱性DNase活性的特征性变化，可能是开发一种用于治疗预后和监测癌症患者的有用检测方法的基础。酸性DNase在恶性肿瘤细胞中被维生素C（抗坏血酸钠）选择性地重新激活，而碱性DNase被维生素K3重新激活。联合使用维生素C和K3在体外和体内均能抑制肿瘤生长，增强和致敏化疗和/或放疗，并减少实验性肿瘤动物的转移数量。联合使用维生素C和K3可被视为一种可能的新型无毒辅助癌症治疗方法，它可以很容易地引入临床癌症治疗的经典方案中，而不会给患者带来任何额外风险。
